Target Validation Information
Target ID T83813
Target Name 5-hydroxytryptamine 2C receptor
Target Type
Successful
Drug Potency against Target (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine Drug Info Ki = 63 nM
N-(pyridin-3-yl)indoline-1-carboxamide Drug Info Ki = 1259 nM
Nefazodone Drug Info Ki = 0.1+/-0.09 microM [553232]
5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Drug Info Ki = 79 nM
(R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine Drug Info Ki = 4 nM
(R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 6.3 nM
1-((R)-2-aminopropyl)-1H-indazol-6-ol Drug Info Ki = 34 nM [527952]
WAY-466 Drug Info Ki = 235 nM [527381]
VER-5384 Drug Info Ki = 8.7 nM [527037]
1-((S)-2-aminopropyl)-1H-indazol-6-ol Drug Info Ki = 3 nM [527952]
(2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine Drug Info Ki = 32 nM [529168]
VOLINANSERIN Drug Info Ki = 13 nM [530936]
1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol Drug Info Ki = 1 nM [527952]
CHLOROPHENYLPIPERAZINE Drug Info Ki = 17 nM [530589]
BARETTIN Drug Info Ki = 340 nM [528498]
PRUVANSERIN Drug Info Ki = 557 nM [528150]
6-bromoaplysinopsin Drug Info Ki = 330 nM [526321]
4-(piperazin-1-yl)furo[3,2-c]pyridine Drug Info Ki = 22 nM [530516]
1-(2-aminoethyl)-1H-indazol-6-ol Drug Info Ki = 9.6 nM [527952]
3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol Drug Info Ki = 125 nM [527668]
4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Drug Info Ki = 755 nM [530516]
1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol Drug Info Ki = 4.8 nM [527952]
1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol Drug Info Ki = 1.2 nM [527952]
2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline Drug Info Ki = 45 nM [530516]
4-(piperazin-1-yl)thieno[2,3-d]pyrimidine Drug Info Ki = 127 nM [530516]
3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol Drug Info Ki = 539 nM [527668]
6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine Drug Info Ki = 207 nM [530516]
5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine Drug Info Ki = 152 nM [529148]
3-(2-Dimethylamino-propyl)-1H-indol-4-ol Drug Info Ki = 126 nM [527668]
5,6-dichloro-3,4-dihydroquinazolin-2-amine Drug Info Ki = 208 nM [529148]
6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine Drug Info Ki = 156 nM [530516]
Ro-60-0175 Drug Info Ki = 26 nM [529168]
7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine Drug Info Ki = 20 nM [529221]
3-Dimethylaminomethyl-1H-indol-4-ol Drug Info Ki = 12.6 nM [527668]
4-(piperazin-1-yl)thieno[3,2-d]pyrimidine Drug Info Ki = 113 nM [530516]
YM-348 Drug Info Ki = 0.89 nM [529221]
NELOTANSERIN Drug Info Ki = 110 nM [531083]
WAY-181187 Drug Info Ki = 124 nM [529112]
(R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 4 nM
WAY-208466 Drug Info IC50 = 644 nM [530209]
SR46349B Drug Info Ki = 0.35 nM [553190]
GR-127935 Drug Info Ki = 105 nM [527726]
(2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine Drug Info Ki = 16 nM [529168]
(R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 7.9 nM
8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine Drug Info Ki = 556 nM [529148]
N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide Drug Info IC50 = 542 nM [529582]
(+/-)-nantenine Drug Info Ki = 1069 nM [530558]
6-bromo-2'-de-N-methylaplysinopsin Drug Info Ki = 2300 nM [526321]
Mirtazapine Drug Info Ki = 5.5 nM [552847]
N-3'-ethylaplysinopsin Drug Info Ki = 3500 nM [526321]
Cyclo[(6-bromotryptophan)arginine] Drug Info Ki = 4630 nM [528498]
SEROTONIN Drug Info Ki = 20 nM [528498]
VER-5593 Drug Info Ki = 3.2 nM [527037]
VER-3323 Drug Info Ki = 24 nM [527037]
5-chloro-3,4-dihydroquinazolin-2-amine Drug Info Ki = 658 nM [529148]
(E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine Drug Info Ki = 200 nM [528690]
APLYSINOPSIN Drug Info Ki = 14451 nM
OCTOCLOTHEPIN Drug Info Ki = 0.57 nM [531171]
4-(piperazin-1-yl)thieno[3,2-c]pyridine Drug Info Ki = 14 nM [530516]
1-(piperazin-1-yl)isoquinoline Drug Info IC50 = 24 nM [530516]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [531079]
VER-2692 Drug Info Ki = 1.6 nM [527833]
SB-271046 Drug Info Ki = 530 nM [529191]
5-MEO-DMT Drug Info Ki = 42 nM [527952]
PRUVANSERIN Drug Info Ki = 645 nM [531083]
2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine Drug Info Ki = 8.3 nM [527952]
1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol Drug Info Ki = 3.6 nM [527952]
6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide Drug Info Ki = 50 nM
3-(3-Dimethylamino-propyl)-1H-indol-4-ol Drug Info Ki = 84 nM [527668]
1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol Drug Info Ki = 14 nM [527668]
[2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine Drug Info Ki = 84 nM [527668]
5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine Drug Info Ki = 380 nM [529148]
6-(piperazin-1-yl)-9-propyl-9H-purine Drug Info Ki = 378 nM [530516]
(2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine Drug Info Ki = 0.2 nM [529168]
PG-01037 Drug Info Ki = 47 nM [528974]
3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol Drug Info Ki = 1772 nM [527668]
(2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine Drug Info Ki = 43 nM [529168]
(S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine Drug Info Ki = 1 nM
7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine Drug Info Ki = 23 nM [529221]
RS-102,221 Drug Info IC50 = 8.3 nM [529789]
3-(2-Dimethylamino-ethyl)-1H-indol-6-ol Drug Info Ki = 6800 nM [527668]
1-(2-Dimethylamino-ethyl)-1H-indol-4-ol Drug Info Ki = 4200 nM [527668]
3-(2-Amino-propyl)-1H-indol-5-ol Drug Info Ki = 7 nM [527952]
3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol Drug Info Ki = 33 nM [527668]
6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine Drug Info Ki = 8.8 nM [529221]
Action against Disease Model Methysergide IC50 on synergistic interaction between arachidonic acid and 5-hydroxytryptamine in h uMan platelets: 5.2nM/L [552384] Drug Info
References
Ref 553232Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol. 1996 Apr;41(4):339-43.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527381J Med Chem. 2005 Jan 27;48(2):353-6.Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.
Ref 527037Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.Indoline derivatives as 5-HT(2C) receptor agonists.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 529168Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Ref 530936Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. Epub 2010 Apr 24.Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 530589Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. Epub 2009 Dec 6.Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.
Ref 528498J Nat Prod. 2006 Oct;69(10):1421-4.Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands.
Ref 528150Bioorg Med Chem Lett. 2006 Jun 15;16(12):3201-4. Epub 2006 May 2.A new class of selective, non-basic 5-HT2A receptor antagonists.
Ref 526321J Nat Prod. 2002 Apr;65(4):476-80.New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 529168Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Ref 529221Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. Epub 2007 Dec 8.Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 529221Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. Epub 2007 Dec 8.Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
Ref 531083J Med Chem. 2010 Aug 12;53(15):5696-706.Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
Ref 529112J Med Chem. 2007 Nov 15;50(23):5535-8. Epub 2007 Oct 19.Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.
Ref 552384Synergism interaction between arachidonic acid by 5-hydroxytryptamine in human platelet aggregation is mediated through multiple signalling pathways. Acta Pharmacol Sin. 2003 Oct;24(10):958-64.
Ref 530209Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. Epub 2009 May 29.Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.
Ref 553190(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther. 1995 Apr;273(1):101-12.
Ref 527726Bioorg Med Chem Lett. 2005 Nov 1;15(21):4786-9.Synthesis of potent and selective serotonin 5-HT1B receptor ligands.
Ref 529168Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 529582Bioorg Med Chem Lett. 2008 Jul 15;18(14):3844-7. Epub 2008 Jun 21.Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.
Ref 530558Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
Ref 526321J Nat Prod. 2002 Apr;65(4):476-80.New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea.
Ref 5528475-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76.
Ref 526321J Nat Prod. 2002 Apr;65(4):476-80.New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea.
Ref 528498J Nat Prod. 2006 Oct;69(10):1421-4.Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands.
Ref 528498J Nat Prod. 2006 Oct;69(10):1421-4.Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands.
Ref 527037Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.Indoline derivatives as 5-HT(2C) receptor agonists.
Ref 527037Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70.Indoline derivatives as 5-HT(2C) receptor agonists.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 528690Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8. Epub 2007 Feb 2.2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands.
Ref 531171J Med Chem. 2010 Oct 14;53(19):7021-34.Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for |A(1)-adrenoceptors.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 531079J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Ref 527833Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. Epub 2005 Oct 27.Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists.
Ref 529191Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. Epub 2007 Nov 17.Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 531083J Med Chem. 2010 Aug 12;53(15):5696-706.Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 529148Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. Epub 2007 Oct 30.Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.
Ref 530516Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. Epub 2009 Oct 30.Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
Ref 529168Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Ref 528974J Med Chem. 2007 Aug 23;50(17):4135-46. Epub 2007 Aug 2.Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 529168Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. Epub 2007 Nov 4.Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
Ref 529221Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. Epub 2007 Dec 8.Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.
Ref 529789J Med Chem. 2008 Nov 27;51(22):7094-8.cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 527952J Med Chem. 2006 Jan 12;49(1):318-28.1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity.
Ref 527668Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9.SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist.
Ref 529221Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. Epub 2007 Dec 8.Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.